HK1218552A1 - 有特異性的抗體結合位點 - Google Patents

有特異性的抗體結合位點

Info

Publication number
HK1218552A1
HK1218552A1 HK16106459.3A HK16106459A HK1218552A1 HK 1218552 A1 HK1218552 A1 HK 1218552A1 HK 16106459 A HK16106459 A HK 16106459A HK 1218552 A1 HK1218552 A1 HK 1218552A1
Authority
HK
Hong Kong
Prior art keywords
egfrviii
binding sites
antibody binding
sites specific
specific
Prior art date
Application number
HK16106459.3A
Other languages
English (en)
Inventor
克里斯蒂娜‧埃爾旺格
烏維‧羅伊施
伊維卡‧法斯克
斯特凡‧奈克馬斯
薇拉‧莫爾肯斯恩
梅爾文‧利特爾
尤金‧朱可夫斯基
Original Assignee
Affimed Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affimed Gmbh filed Critical Affimed Gmbh
Publication of HK1218552A1 publication Critical patent/HK1218552A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
HK16106459.3A 2013-08-07 2016-06-06 有特異性的抗體結合位點 HK1218552A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13179630 2013-08-07
EP13189599 2013-10-21
PCT/EP2014/002177 WO2015018527A1 (en) 2013-08-07 2014-08-07 ANTIBODY BINDING SITES SPECIFIC FOR EGFRvIII

Publications (1)

Publication Number Publication Date
HK1218552A1 true HK1218552A1 (zh) 2017-02-24

Family

ID=51453717

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16106459.3A HK1218552A1 (zh) 2013-08-07 2016-06-06 有特異性的抗體結合位點

Country Status (14)

Country Link
US (1) US10273309B2 (zh)
EP (1) EP3030581B1 (zh)
JP (1) JP6529498B2 (zh)
CN (1) CN105555804B (zh)
AU (1) AU2014304930B2 (zh)
CA (1) CA2920173C (zh)
DK (1) DK3030581T3 (zh)
HK (1) HK1218552A1 (zh)
HR (1) HRP20210561T1 (zh)
HU (1) HUE054057T2 (zh)
LT (1) LT3030581T (zh)
RU (1) RU2696892C2 (zh)
SI (1) SI3030581T1 (zh)
WO (1) WO2015018527A1 (zh)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3126388T3 (pl) 2014-03-11 2019-10-31 Regeneron Pharma Przeciwciała anty-egfrviii i ich zastosowania
US9212225B1 (en) * 2014-07-01 2015-12-15 Amphivena Therapeutics, Inc. Bispecific CD33 and CD3 binding proteins
EP2982693A1 (en) * 2014-08-07 2016-02-10 Affimed Therapeutics AG CD3 binding domain
AU2014412643B2 (en) * 2014-11-25 2018-08-30 Pharmabcine Inc. Novel EGFRvIII antibody and composition comprising same
CN114652827A (zh) 2015-05-29 2022-06-24 安普希韦纳治疗公司 双特异性cd33和cd3结合蛋白质的使用方法
CN108289950B (zh) 2015-06-09 2022-10-21 纪念斯隆凯特琳癌症中心 特异于人hla呈递的ebv潜伏膜蛋白2a肽的t细胞受体样抗体药剂
WO2016204966A1 (en) * 2015-06-16 2016-12-22 Genentech, Inc. Anti-cd3 antibodies and methods of use
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
TWI744242B (zh) * 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
US10221242B2 (en) 2016-01-21 2019-03-05 Pfizer Inc. Antibodies specific for epidermal growth factor receptor variant III and their uses
TWI755547B (zh) 2016-01-21 2022-02-21 美商輝瑞股份有限公司 靶向表皮生長因子受體變異體iii之嵌合型抗原受體
EA039859B1 (ru) * 2016-02-03 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
CN107556386A (zh) * 2016-06-30 2018-01-09 中国科学院深圳先进技术研究院 抗EGFRvIII和CD3特异性双靶向抗体、含双靶向抗体表达盒的微环DNA及应用
RU2721582C1 (ru) * 2016-08-05 2020-05-20 И-Байолоджикс Инк. Антитела против лиганда-1 запрограммированной смерти (PD-L1) и их применение
RU2725950C1 (ru) 2016-08-05 2020-07-07 И-Байолоджикс Инк. Антитела против белка-1 запрограммированной клеточной смерти (pd-1) и их применение
CN106501518A (zh) * 2017-01-06 2017-03-15 北京弘润天源生物技术股份有限公司 一种检测EGFRvⅢ的免疫组化抗体试剂及检测方法
EP3589655B1 (en) * 2017-02-28 2022-10-26 Affimed GmbH Tandem-diabody for cd16a-directed nk-cell engagement
AU2019218959A1 (en) 2018-02-08 2020-09-03 Genentech, Inc. Bispecific antigen-binding molecules and methods of use
KR20200132919A (ko) * 2018-03-14 2020-11-25 아피메트 게엠베하 이중특이적 egfr/cd16 항원-결합 단백질
TWI829831B (zh) * 2018-12-21 2024-01-21 瑞士商赫孚孟拉羅股份公司 結合cd3之抗體
PE20221511A1 (es) 2019-12-13 2022-10-04 Genentech Inc Anticuerpos anti-ly6g6d y metodos de uso
WO2022159685A2 (en) * 2021-01-22 2022-07-28 Vanderbilt University Sars-cov-2 coronavirus antibodies and uses thereof
WO2023287941A2 (en) * 2021-07-16 2023-01-19 Medical Guidance Systems, Llc Anti-tax interacting protein-1 (tip1) binding molecules
CN116375868A (zh) * 2021-12-31 2023-07-04 康源博创生物科技(北京)有限公司 一种抗cd3的人源化抗体及其在制备双特异性抗体中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19819846B4 (de) * 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalente Antikörper-Konstrukte
EP1266009B1 (en) * 2000-02-25 2008-12-31 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES ANTI-EGFRvIII SCFVS WITH IMPROVED CYTOTOXICITY AND YIELD, IMMUNOTOXINS BASED THEREON, AND METHODS OF USE THEREOF
US20100056762A1 (en) * 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
BRPI0411852A (pt) * 2003-06-27 2006-05-23 Abgenix Inc anticorpos dirigidos aos mutantes de deleção de receptor de fator de crescimento epidérmico e seu usos

Also Published As

Publication number Publication date
CN105555804B (zh) 2020-12-25
LT3030581T (lt) 2021-05-25
HUE054057T2 (hu) 2021-08-30
EP3030581B1 (en) 2021-01-20
JP6529498B2 (ja) 2019-06-12
JP2016536322A (ja) 2016-11-24
HRP20210561T1 (hr) 2021-05-14
CA2920173C (en) 2021-08-10
CN105555804A (zh) 2016-05-04
DK3030581T3 (da) 2021-04-12
WO2015018527A1 (en) 2015-02-12
BR112016002610A8 (pt) 2018-01-23
BR112016002610A2 (pt) 2017-09-12
RU2696892C2 (ru) 2019-08-07
CA2920173A1 (en) 2015-02-12
AU2014304930B2 (en) 2019-11-21
US10273309B2 (en) 2019-04-30
US20160152728A1 (en) 2016-06-02
AU2014304930A1 (en) 2016-02-25
SI3030581T1 (sl) 2021-07-30
EP3030581A1 (en) 2016-06-15
RU2016106577A (ru) 2017-09-14

Similar Documents

Publication Publication Date Title
HK1218552A1 (zh) 有特異性的抗體結合位點
IL269528A (en) Anti- FCRH5 antibodies
HK1217023A1 (zh) 新型抗體
GB201322583D0 (en) Antibodies
HK1217500A1 (zh) 特異性結合 的抗體
HK1220142A1 (zh) 抗體
GB201308658D0 (en) Antibodies
GB201315486D0 (en) Antibodies
GB201300706D0 (en) Antibody
IL245488A0 (en) Anti- ccl17 antibodies
HK1218921A1 (zh) 特異性結合 的抗體
GB201318283D0 (en) Antibodies